[Anti-tau therapies-what can be expected?]

Anti-Tau-Therapien – was können wir erwarten?
Alzheimer Disease / therapy Amyloid beta-Peptides / metabolism Humans Immunotherapy Oligonucleotides, Antisense / therapeutic use tau Proteins / antagonists & inhibitors
Alzheimer’s disease Antisense oligonucleotides Immunization Intervention trials Tau pathologies

Journal

Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773

Informations de publication

Date de publication:
Sep 2019
Historique:
pubmed: 25 7 2019
medline: 26 9 2019
entrez: 24 7 2019
Statut: ppublish

Résumé

Alzheimer's disease is histopathologically characterized by aggregation of two proteins, namely amyloid-beta peptide and tau protein. Whereas former intervention trials focused particularly on the amyloid pathology, recent therapeutic approaches are directed against the tau pathology. This article summarizes recent progress in anti-tau therapies, especially therapies based on anti-tau immunization and antisense oligonucleotides (ASO).

Identifiants

DOI: 10.1007/s00115-019-0758-7 PMID: 31332452
pubmed: 31332452
doi: 10.1007/s00115-019-0758-7
pii: 10.1007/s00115-019-0758-7
doi:

Substances chimiques

Amyloid beta-Peptides 0
Oligonucleotides, Antisense 0
tau Proteins 0

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

891-897

Références

Acta Neuropathol. 2002 Jan;103(1):26-35
pubmed: 11837744
Neurology. 2003 Jul 8;61(1):46-54
pubmed: 12847155
J Cell Biol. 2004 Oct 11;167(1):99-110
pubmed: 15466480
Science. 2007 May 4;316(5825):750-4
pubmed: 17478722
J Biol Chem. 2009 Jul 31;284(31):20909-16
pubmed: 19491104
Cell. 2010 Aug 6;142(3):387-97
pubmed: 20655099
J Neuropathol Exp Neurol. 2012 May;71(5):362-81
pubmed: 22487856
Int J Alzheimers Dis. 2012;2012:873270
pubmed: 22720190
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
PLoS One. 2013 Aug 19;8(8):e72301
pubmed: 23977276
J Alzheimers Dis. 2015;45(1):75-88
pubmed: 25537011
J Alzheimers Dis. 2015;48(2):403-10
pubmed: 26402004
Nat Rev Neurosci. 2016 Jan;17(1):5-21
pubmed: 26631930
Expert Rev Neurother. 2016;16(3):259-77
pubmed: 26822031
Biochim Biophys Acta. 2016 Oct;1862(10):1909-17
pubmed: 27460705
Lancet Neurol. 2017 Feb;16(2):123-134
pubmed: 27955995
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123067
Curr Alzheimer Res. 2018;15(3):283-300
pubmed: 28413986
Mayo Clin Proc. 2017 Aug;92(8):1291-1303
pubmed: 28778262
Traffic. 2018 Feb;19(2):111-121
pubmed: 29077261
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
N Engl J Med. 2018 Feb 15;378(7):625-635
pubmed: 29443664
BMB Rep. 2018 Jun;51(6):265-273
pubmed: 29661268
Ther Adv Neurol Disord. 2018 May 23;11:1756286418776932
pubmed: 29854003
Curr Biol. 2018 Jul 9;28(13):2181-2189.e4
pubmed: 30008334
J Alzheimers Dis. 2018;66(2):855-856
pubmed: 30400102
Front Neurosci. 2018 Nov 02;12:798
pubmed: 30450030
J Prev Alzheimers Dis. 2019;6(1):63-69
pubmed: 30569088
Br J Psychiatry. 2019 Apr 5;:1-7
pubmed: 30947755

Auteurs

Klaus Fließbach (K)

Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Universitätsklinikum Bonn Venusberg, Campus 1, 53127, Bonn, Deutschland.
Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE, Bonn, Deutschland.

Cornelia McCormick (C)

Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Universitätsklinikum Bonn Venusberg, Campus 1, 53127, Bonn, Deutschland.
Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE, Bonn, Deutschland.

Barbara Kaulen (B)

Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Universitätsklinikum Bonn Venusberg, Campus 1, 53127, Bonn, Deutschland.
Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE, Bonn, Deutschland.

Anja Schneider (A)

Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Universitätsklinikum Bonn Venusberg, Campus 1, 53127, Bonn, Deutschland. anja.schneider@dzne.de.
Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE, Bonn, Deutschland. anja.schneider@dzne.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › [Anti-tau therapies-what can be expected?]
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › [Anti-tau therapies-what can be expected?]
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [Anti-tau therapies-what can be expected?]
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › [Anti-tau therapies-what can be expected?]
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Sondes moléculaires › Sondes d'acide nucléique › Éléments antisens (génétique) › Oligonucléotides antisens › [Anti-tau therapies-what can be expected?]
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › [Anti-tau therapies-what can be expected?]